Treatment Action Group

Hepatitis C and TB Long-Acting Medicines: Analysis of Patenting Trends and Implications for Access

Treatment Action Group releases a patent landscape investigating potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines.

Read More →

Webinar on long-acting technologies

On 4 November 2021, Treatment Action Group (TAG) and the International Treatment Preparedness Coalition (ITPC) will co-host a webinar, 'Same Meds, New Patents: What Do Activists Need to Know About Long-Acting Technologies', to present the main findings of the upcoming report 'Hepatitis C and Tuberculosis Long-Acting Medicines: Analysis on Patenting Trends.'

Read More →

An Activist’s Guide to Shorter Treatment for Drug-Sensitive TB

This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

Read More →

TAGline: Delivering on the promise of long-acting formulations

October 2021 issue of TAGline delves deep into the development of long-acting formulations for the treatment and prevention of HIV, TB, hepatitis C, and malaria.

Read More →

TAG's 2021 Pipeline Report: TB chapters released

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Read More →

Substantial public investments in GeneXpert underscore need for affordable pricing

PLOS ONE publishes TAG’s comprehensive analysis of public investments in the development of rapid technology for diagnosing infectious diseases.

Read More →

TB CAB evaluation survey

Take a short survey and help evaluate the first 10 years of the Global TB CAB!

Read More →

CAB compensation survey

Take a quick Community Advisory Board (CAB) compensation survey and help define how to best support CAB members!

Read More →

TAG launches new TB training resources

The tools are meant to help build awareness of TB in communities, share information on the latest scientific and policy developments, and inform activism to address barriers to TB diagnosis, treatment, and care.

Read More →

Landmark TB trials results published in New England Journal of Medicine

A shorter regimen containing rifapentine and moxifloxacin can cure TB in four months.

Read More →

Page 1 of 18 · Total posts: 10

1 2 Last→